1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biosimilars Business Review Q2 2015

Biosimilars Business Review Q2 2015

  • June 2015
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - FDA Will Continue To Face Criticism Until Interchangeability And Naming Issues Are Resolved
Industry Brief - Pfenex Collaboration With Hospira Gains Early HSR Clearance
Industry Brief - EMA Validates Biogen's Infliximab For Review
Industry Brief - Hospira's Infliximab Launched In Canada
Industry Brief - Coherus And Baxter Amend Etanercept Biosimilar Collaboration
Industry Brief - Tev-Tropin Brandname Changed To Zomacton
Industry Trend Analysis - Biosimilar Battle Between Hospira And Sandoz Will Intensify
Industry Brief - Ligand Acquires Rights to Biologic/Biosimilar Programmes From Selexis
Industry Trend Analysis - Latest US Biosimilar Legislation Provides A Model That Will Resolve Key Concern
Industry Brief - JHL Biotech Raises New Funds
Industry Brief - Epirus And mAbxience Enter Latin America Infliximab Deal
Industry Trend Analysis - J&J Will Rely On An Expanded Immunology Portfolio To Offset Growing Remicade Competition
Industry Brief - Hospira To Provide Theradiag's Lisa Tracker Infiximab Monitoring Kit With Inflectra
Industry Brief - amp Out-Licenses Biosimilar MAb
Industry Brief - First Biosimilar Infliximab Approved In Brazil
Industry Brief - amp Out-Licenses Second Biosimilar
Industry Trend Analysis - Interchangeability Guidance Will Be Essential For US Biosimilar Market To Flourish

Table Of Contents

Biosimilars Business Review Q2 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.